Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Sotio Biotech Inc.
Stanford University
University of Virginia
Seagen Inc.
Fusion Pharmaceuticals Inc.
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Bolt Biotherapeutics, Inc.
Novartis
Nuvation Bio Inc.
Actym Therapeutics, Inc.
Taiho Oncology, Inc.
NiKang Therapeutics, Inc.
Vall d'Hebron Institute of Oncology
Sanofi
Eli Lilly and Company
University of Pennsylvania
Numab Therapeutics AG
Cancer Trials Ireland
University of Virginia
Sanofi
Orum Therapeutics USA, Inc.
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Mayo Clinic
Novartis
Massachusetts General Hospital
Pfizer
M.D. Anderson Cancer Center
Black Diamond Therapeutics, Inc.
Turnstone Biologics, Corp.
Tvardi Therapeutics, Incorporated
Accutar Biotechnology Inc
Seagen Inc.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NantBioScience, Inc.
Medical University of South Carolina
Novartis
Hoffmann-La Roche
Pfizer
GlaxoSmithKline
Pfizer
Pfizer
National Cancer Institute (NCI)
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
Washington University School of Medicine
Exelixis